The immune system plays a central role in the pathophysiology of many of the most important human diseases, including infection, autoimmunity and cancer. Recent advances in our understanding of the importance of the innate immune system in maintaining immune homeostasis is leading to increasing focus on modulation of innate immunity in the treatment of many of these diseases.
Critical to these advances in understanding are the role of innate immune epigenetics and metabolism, including the complex interactions between glucose, lipid and other metabolic pathways in innate immune cells.
IRI has established a world-leading position in the isolation, characterization and mechanistic biology of beta 1,3 1,6 glucans which are pathogen associated molecular patterns (PAMPs). These beta glucans are associated with complex structural and immunobiology in interactions with both circulating innate immune cells and their progenitors, uniquely positioning them for development as systemic therapeutics in a wide range of diseases associated with immunopathophysiology.